Skip to Content
Search Menu

The Risk of Hypothyroidism in Breast Cancer Patients Treated with Anti-oestrogens Tamoxifen and Letrozole

Anti-oestrogen tamoxifen, but not letrozole, is related to the risk of subclinical hypothyroidism and can influence the observed weight gain in breast cancer patients.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Relateret indhold

Giuseppe Viale

Trastuzumab Deruxtecan May Become New Standard of Care After ≥1 Endocrine-Based Therapy for Patients with HER2-low and -ultralow, HR+ mBC

/ Giuseppe Viale
Breast cancerESMO24 Play the Video 4:51
Nancy Lin

New Hope for Patients with Breast Cancer Including Patients with Brain Metastases

/ Nancy Lin
Breast cancerESMO24 Play the Video 1:23

New Data on Trastuzumab Deruxtecan Shows Promising Outcomes in HER2-Positive Metastatic Breast Cancer with Brain Metastases: Results from DESTINY-Breast12

/ Jan Andreasen
Breast cancerESMO24

ESMO24: Breastfeeding After Breast Cancer Treatment Is Safe

/ Sofie Pohl
Breast cancerESMO24

Consecutive Mammography Screening Is the Best Way to Reduce the Risk of Premature Death from Breast Cancer

/ Sofie Pohl
Breast cancer

Recent Updates in Breast Cancer Screening – A Norwegian Perspective

/ Kaitlyn Tsuruda / Solveig Hofvind
Breast cancer
László Tabár

Mammography Screening Is the Best Way to Reduce the Risk of a Premature Death from Breast Cancer

/ László Tabár
Breast cancer Play the Video 7:11

ASCO GI 2024: Targeting HER2 in Gastroesophageal Adenocarcinoma

/ Sofie Pohl
ASCOGI24Breast cancerGastrointestinal cancer
Hatem Azim

Using Fertility Options May be Safe for Patients with HR-positive Breast Cancer

/ Hatem Azim
Breast cancerSABCS23 Play the Video 10:10
Back to top